What is Pepticom?
Pepticom operates at the intersection of artificial intelligence and medicinal chemistry, specializing in the design of novel peptide drug candidates. By utilizing sophisticated biocomputational software, the company optimizes the discovery process, effectively reducing the time and financial risk associated with bringing new therapeutics to market. Their proprietary platform is engineered to identify superior binding peptides, offering a robust solution for complex target interactions that have historically challenged conventional drug development.
The company's market position is defined by its ability to bridge the gap between computational modeling and clinical application. Through a dual strategy of internal development and strategic industry collaborations, Pepticom is positioning itself as a key player in the next generation of peptide-based medicine, focusing on high-efficacy drug candidates that address unmet medical needs.
How much funding has Pepticom raised?
Pepticom has raised a total of $14.2M across 3 funding rounds:
Series A
$5M
Other Financing Round
$2.6M
Series A
$6.6M
Series A (2019): $5M with participation from Chartered Group
Other Financing Round (2021): $2.6M led by The Chartered Group
Series A (2025): $6.6M supported by Japan Israel High Tech Ventures 2 LP
Key Investors in Pepticom
Japan Israel High Tech Ventures 2 LP
A venture capital firm focused on fostering technological synergy and innovation between the Japanese and Israeli high-tech ecosystems.
The Chartered Group
A global investment firm with a diverse portfolio, often providing strategic capital to companies demonstrating high growth potential in specialized technology sectors.
Chartered Group
An investment entity providing sustained financial support to early-stage and growth-oriented technology enterprises.
What's next for Pepticom?
With the recent influx of capital, Pepticom is well-positioned to accelerate its discovery projects and enhance its computational infrastructure. The strategic focus will likely shift toward deepening its collaborative partnerships with major pharmaceutical entities, leveraging its AI-driven platform to validate new therapeutic targets. As the company moves further into the development lifecycle, the emphasis will remain on scaling its proprietary technology to maintain a competitive edge in the rapidly evolving landscape of biocomputational drug discovery.
Future growth will be contingent upon the successful translation of its in-silico designs into viable clinical candidates. By maintaining a rigorous focus on reducing development costs and improving the success rate of peptide therapeutics, Pepticom is poised to play a pivotal role in the modernization of 21st-century medicine.
